Initial therapy with protease inhibitor-sparing regimens: Evaluation of nevirapine and delavirdine

11Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We have compared the results (on-treatment analyses) of 2 randomized clinical trials of protease inhibitor-sparing regimens in drug-naive patients. In the INCAS (Italy, Netherlands, Canada, Australia) study, the mean decrease in plasma viral load over 52 weeks was 2.2 log10 copies/mL in 40 patients who were receiving zidovudine/didanosine/nevirapine (18 [45%] had maximal suppression), with a mean increase in CD4 T cell counts of 139 cells/μL. In protocol 0021 Part II, the mean decrease in plasma viral load over 52 weeks was 2.1 log10 copies/mL in 34 patients who were receiving zidovudine/lamivudine/delavirdine (20 [59%] had maximal suppression), with a mean increase in CD4 T cell counts of 88 cells/μL. The virologic and immunologic efficacy of the 2 triple-drug regimens are similar. Until results of long-term studies are available to establish whether a preferred approach to initial therapy exists, non-nucleoside reverse transcriptase inhibitors may be a valuable alternative to protease inhibitors in the initial therapy of antiretroviral-naive, moderately immunosuppressed patients.

Cite

CITATION STYLE

APA

Conway, B. (2000). Initial therapy with protease inhibitor-sparing regimens: Evaluation of nevirapine and delavirdine. In Clinical Infectious Diseases (Vol. 30). https://doi.org/10.1086/313850

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free